k141_80706_12	CARD|gb|ATC67679.1|ARO:3000838|arlR	34.2	117	911	219	7.55e-18	82.4
k141_80706_12	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.2	117	911	219	7.25e-16	76.6
k141_80706_12	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.2	117	911	219	7.25e-16	76.6
k141_80706_12	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.2	117	911	220	7.40e-16	76.6
k141_80706_12	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.2	117	911	220	1.00e-15	76.3
k141_80706_12	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	33.3	123	911	228	1.32e-14	73.2
k141_80706_18	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.1	134	329	231	3.76e-16	75.5
k141_80706_18	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.1	124	329	232	9.08e-13	65.9
k141_148392_6	SARG|CAA37477	28.1	360	601	663	4.63e-31	127
k141_148392_6	SARG|ABI81214	29.6	388	601	639	2.44e-29	122
k141_148392_6	SARG|ABB70054	29.4	388	601	639	7.75e-29	120
k141_148392_6	SARG|YP_002738300	29.4	388	601	639	7.75e-29	120
k141_148392_6	SARG|BAB71968	29.1	388	601	639	1.84e-28	119
k141_148392_6	SARG|gi|319894056|gb|ADV76307.1|	29.1	388	601	639	2.46e-28	119
k141_148392_6	SARG|X04388.gene.p01	29.1	388	601	639	2.46e-28	119
k141_148392_6	SARG|FN594949.1.gene24.p01	25.8	438	601	640	1.36e-25	110
k141_148392_6	NCBI|WP_003454408.1|1|1|tet(44)|tet(44)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(44)|AMR|tetracycline	40.1	142	601	640	7.52e-25	108
k141_148392_6	SARG|Q02652	41.8	134	601	639	3.02e-23	103
k141_27554_5	ResF|penA_1_AF515059_1	25.0	599	720	581	2.45e-31	128
k141_81092_3	SARG|gi|851901342|ref|WP_048211771.1|	23.1	455	480	457	4.14e-14	73.2
k141_81092_3	SARG|gi|491269060|ref|WP_005127195.1|	23.1	455	480	457	5.51e-14	72.8
k141_81092_3	SARG|ZP_02903251	23.4	449	480	457	5.51e-14	72.8
k141_81092_3	SARG|gi|545292767|ref|WP_021573603.1|	23.6	449	480	457	2.29e-13	70.9
k141_81092_3	SARG|gi|754952496|ref|WP_042308660.1|	23.3	455	480	457	2.29e-13	70.9
k141_81092_3	SARG|gi|1002398650|ref|WP_061381408.1|	23.1	455	480	457	2.29e-13	70.9
k141_81092_3	SARG|Q0T4A9	23.1	455	480	457	3.04e-13	70.5
k141_81092_3	SARG|gi|485757462|ref|WP_001382958.1|	23.2	449	480	457	4.04e-13	70.1
k141_81092_3	SARG|gi|851908704|ref|WP_048214273.1|	22.9	455	480	457	4.04e-13	70.1
k141_81092_3	SARG|gi|487508322|ref|WP_001706332.1|	23.2	449	480	457	4.04e-13	70.1
k141_81092_16	SARG|gb|AAC74000.1|ARO:3003950|msbA	38.0	500	609	582	1.55e-100	316
k141_81092_16	SARG|gi|664556405|ref|WP_031071225.1|	34.9	495	609	602	1.29e-91	293
k141_81092_16	SARG|gi|493394434|ref|WP_006350564.1|	33.7	495	609	602	3.57e-91	292
k141_81092_16	SARG|gi|739906046|ref|WP_037756452.1|	34.9	522	609	620	2.15e-90	291
k141_81092_16	SARG|gi|516574297|ref|WP_017949361.1|	34.7	522	609	620	1.63e-89	288
k141_81092_16	SARG|gi|662754041|ref|WP_030125200.1|	33.7	495	609	601	2.81e-89	287
k141_81092_16	SARG|gi|505389066|ref|WP_015576168.1|	33.7	495	609	601	2.81e-89	287
k141_81092_16	SARG|gi|503923650|ref|WP_014157644.1|	33.7	495	609	601	3.94e-89	287
k141_81092_16	SARG|gi|764446018|ref|WP_044369325.1|	33.9	495	609	605	6.10e-89	286
k141_81092_16	SARG|gi|1045390184|ref|WP_065479071.1|	33.9	495	609	605	6.10e-89	286
k141_81092_20	SARG|ZP_04606269	27.6	145	181	299	2.54e-08	51.2
k141_175436_2	SARG|FJ872411.1.gene41.p01	32.7	352	336	352	1.67e-51	173
k141_175436_2	SARG|gb|ABX54687.1|ARO:3002910|vanL	32.9	343	336	349	6.03e-51	171
k141_175436_2	SARG|gi|498467695|ref|WP_010773051.1|	31.6	354	336	352	1.58e-47	162
k141_175436_2	NCBI|PBI24747.1|1|1|vanG-Cd|vanG-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--D-serine_ligase_VanG-Cd|AMR|glycopeptide	30.4	375	336	366	4.58e-46	159
k141_175436_2	SARG|gi|1028100561|ref|WP_063856696.1|	30.5	351	336	349	6.09e-46	158
k141_175436_2	SARG|gi|752682279|ref|WP_041330231.1|	30.7	349	336	349	8.54e-46	158
k141_175436_2	SARG|AAF71281	30.2	348	336	349	4.89e-44	153
k141_175436_2	SARG|DQ212986.1.gene8.p01	29.9	348	336	349	2.63e-43	151
k141_175436_2	SARG|gi|405945042|pdb|4FU0|A	29.9	348	336	357	3.15e-43	151
k141_175436_2	SARG|gi|765411304|ref|WP_044689514.1|	29.9	348	336	349	5.16e-43	150
k141_175436_15	SARG|gi|803568669|ref|WP_046077412.1|	25.6	219	252	648	3.41e-08	52.8
k141_175436_15	SARG|gi|446110352|ref|WP_000188207.1|	25.6	219	252	648	3.41e-08	52.8
k141_175436_15	SARG|YP_002382193	25.6	219	252	648	3.41e-08	52.8
k141_175436_15	SARG|gi|803575554|ref|WP_046081557.1|	25.6	219	252	648	3.41e-08	52.8
k141_175436_15	SARG|gi|446110351|ref|WP_000188206.1|	25.6	219	252	648	3.41e-08	52.8
k141_175436_15	SARG|gi|639216333|ref|WP_024554080.1|	26.4	201	252	648	1.47e-07	50.8
k141_175436_15	SARG|gi|495067432|ref|WP_007792257.1|	24.7	194	252	647	1.97e-07	50.4
k141_175436_15	SARG|gi|1001720867|ref|WP_061274204.1|	26.0	219	252	648	1.97e-07	50.4
k141_175436_15	SARG|gi|502669352|ref|WP_012905216.1|	26.9	201	252	648	2.64e-07	50.1
k141_175436_15	SARG|gi|736472622|ref|WP_034494292.1|	26.6	203	252	648	2.64e-07	50.1
k141_175436_19	SARG|AUI09862.1	32.7	284	274	287	1.41e-36	130
k141_175436_19	SARG|gi|638947703|ref|WP_024439711.1|	26.3	274	274	271	1.25e-16	76.6
k141_175436_19	SARG|YP_001746870	29.4	252	274	279	8.26e-15	71.6
k141_175436_21	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	30.6	445	451	451	3.95e-50	175
k141_175436_21	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	30.1	445	451	481	3.72e-49	173
k141_175436_21	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	28.0	443	451	451	1.52e-46	166
k141_202580_1	SARG|gb|AAF40763.1|ARO:3003961|farA	29.5	312	374	384	7.01e-31	120
k141_202580_1	SARG|gi|559225332|ref|WP_023581116.1|	27.9	319	374	392	3.94e-30	118
k141_202580_1	NCBI|CAQ45063.1|1|1|emrA-sm|emrA-sm||1|EFFLUX|EFFLUX|multidrug_efflux_MFS_transporter_periplasmic_adaptor_subunit_EmrA|AMR|efflux	28.4	320	374	393	1.05e-29	117
k141_202580_1	SARG|gi|857587973|emb|CRL59872.1|	28.2	319	374	392	1.96e-29	116
k141_202580_1	SARG|gi|739067214|ref|WP_036938621.1|	27.0	319	374	392	7.02e-29	114
k141_202580_1	SARG|gi|896186420|ref|WP_049196554.1|	27.9	319	374	391	1.31e-28	114
k141_202580_1	SARG|gi|490366423|ref|WP_004246087.1|	27.9	319	374	391	1.31e-28	114
k141_202580_1	SARG|gi|763189942|ref|WP_044067173.1|	28.1	292	374	390	1.78e-28	113
k141_202580_1	SARG|gi|545301157|ref|WP_021580954.1|	28.8	306	374	390	1.78e-28	113
k141_202580_1	SARG|gi|930430030|ref|WP_054192373.1|	28.1	292	374	390	1.78e-28	113
k141_148799_3	SARG|YP_001116032	28.5	316	353	405	3.56e-18	84.0
k141_148799_3	SARG|YP_001583349	27.8	316	353	405	8.76e-18	82.8
k141_148799_3	SARG|gi|667783307|ref|WP_031401782.1|	27.5	316	353	405	1.18e-17	82.4
k141_148799_3	SARG|ZP_02904981	28.2	319	353	405	1.60e-17	82.0
k141_148799_3	SARG|gi|746321235|ref|WP_039367880.1|	27.8	316	353	405	1.60e-17	82.0
k141_148799_3	SARG|YP_001811891	28.4	317	353	405	1.60e-17	82.0
k141_148799_3	SARG|gi|736027032|ref|WP_034187788.1|	27.8	316	353	405	1.60e-17	82.0
k141_148799_3	SARG|YP_371055	27.5	316	353	405	1.60e-17	82.0
k141_148799_3	SARG|YP_776583	28.4	317	353	405	1.60e-17	82.0
k141_148799_3	SARG|gi|749314681|ref|WP_040138758.1|	28.2	316	353	405	1.60e-17	82.0
k141_148799_4	SARG|gb|AAG07064.1|ARO:3003693|mexK	25.0	484	490	1025	4.06e-37	144
k141_148799_4	NCBI|AAO18187.2|1|1|sdeB|sdeB|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_SdeB|AMR|efflux	26.2	478	490	1047	1.07e-35	140
k141_148799_4	SARG|gb|AAL19305.1|ARO:3000790|mdsB	25.8	465	490	1055	1.07e-35	140
k141_148799_4	SARG|gi|966510466|ref|WP_058527057.1|	26.5	479	490	1056	1.14e-34	137
k141_148799_4	SARG|gi|769989475|ref|WP_045105425.1|	25.9	487	490	1068	1.54e-34	137
k141_148799_4	SARG|gi|966514950|ref|WP_058531469.1|	26.1	479	490	1055	6.67e-34	135
k141_148799_4	SARG|gi|966439914|ref|WP_058480237.1|	25.7	474	490	1054	8.95e-34	134
k141_148799_4	SARG|gi|966403553|ref|WP_058447148.1|	26.2	474	490	1058	8.97e-34	134
k141_148799_4	CARD|gb|AAG03548.1|ARO:3003681|TriC	22.7	475	490	1015	1.18e-33	134
k141_148799_4	SARG|gb|CAH14033.1|ARO:3004100|LpeB	25.2	489	490	1014	5.12e-33	132
k141_121830_2	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.3	251	265	655	1.13e-41	150
k141_121830_2	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.9	251	265	655	4.04e-41	148
k141_121830_2	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.9	251	265	655	4.04e-41	148
k141_121830_2	SARG|gb|AKA86814|ARO:3003746|optrA	31.9	251	265	655	4.04e-41	148
k141_121830_2	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.9	251	265	655	1.45e-40	147
k141_121830_2	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.9	251	265	655	1.45e-40	147
k141_121830_2	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.9	251	265	655	1.45e-40	147
k141_121830_2	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.9	251	265	655	1.99e-40	146
k141_121830_2	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.9	251	265	655	1.99e-40	146
k141_121830_2	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.9	251	265	655	2.74e-40	146
k141_162318_6	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	39.9	690	658	703	2.33e-147	443
k141_202811_6	SARG|gi|896325272|ref|WP_049294291.1|	47.0	219	218	648	7.05e-61	200
k141_202811_6	SARG|gi|639216333|ref|WP_024554080.1|	46.6	219	218	648	1.92e-60	199
k141_202811_6	SARG|gi|639225329|ref|WP_024561799.1|	47.0	219	218	648	3.74e-60	198
k141_202811_6	SARG|gi|639218559|ref|WP_024556062.1|	47.0	219	218	648	3.74e-60	198
k141_202811_6	SARG|gi|803568669|ref|WP_046077412.1|	46.6	219	218	648	5.21e-60	197
k141_202811_6	SARG|gi|446110352|ref|WP_000188207.1|	46.6	219	218	648	5.21e-60	197
k141_202811_6	SARG|YP_002382193	46.6	219	218	648	5.21e-60	197
k141_202811_6	SARG|gi|803575554|ref|WP_046081557.1|	46.6	219	218	648	5.21e-60	197
k141_202811_6	SARG|gi|446110351|ref|WP_000188206.1|	46.6	219	218	648	5.21e-60	197
k141_202811_6	SARG|gi|494938585|ref|WP_007664615.1|	46.1	219	218	647	1.00e-59	197
k141_81747_6	SARG|gi|694064328|ref|WP_032410816.1|	31.4	204	229	646	9.11e-27	106
k141_81747_6	SARG|gb|AAC74000.1|ARO:3003950|msbA	30.1	196	229	582	7.41e-15	72.0
k141_81747_6	SARG|gb|WP_082039181.1|ARO:3007028|salD	21.9	215	229	544	2.22e-12	64.7
k141_81747_6	SARG|gi|754608317|ref|WP_041998010.1|	28.8	191	229	612	7.69e-12	63.2
k141_81747_6	SARG|gi|664317010|ref|WP_030845774.1|	28.8	191	229	605	1.03e-11	62.8
k141_81747_6	SARG|gi|663286402|ref|WP_030292859.1|	28.8	191	229	605	1.03e-11	62.8
k141_81747_6	SARG|gi|663342223|ref|WP_030341347.1|	28.8	191	229	605	1.03e-11	62.8
k141_81747_6	SARG|gi|759527374|ref|WP_043247487.1|	28.8	191	229	605	1.03e-11	62.8
k141_81747_6	SARG|gi|664194237|ref|WP_030727956.1|	28.8	191	229	605	1.03e-11	62.8
k141_81747_6	SARG|gi|926286457|ref|WP_053623344.1|	30.5	174	229	605	1.88e-11	62.0
k141_81747_7	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.5	654	651	655	1.23e-108	341
k141_81747_7	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.3	654	651	655	1.23e-108	341
k141_81747_7	SARG|gb|AKA86814|ARO:3003746|optrA	33.3	654	651	655	1.23e-108	341
k141_81747_7	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.5	654	651	655	2.43e-108	340
k141_81747_7	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.5	654	651	655	6.73e-108	339
k141_81747_7	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.3	654	651	655	9.46e-108	338
k141_81747_7	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.3	654	651	655	9.46e-108	338
k141_81747_7	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.3	654	651	655	9.46e-108	338
k141_81747_7	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.3	654	651	655	9.46e-108	338
k141_81747_7	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.3	654	651	655	1.33e-107	338
k141_28466_5	NCBI|WP_032488596.1|1|1|nimA|nimA|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimA|AMR|nitroimidazole	31.5	149	172	176	8.19e-17	72.8
k141_28466_5	megares|MEG_4185|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIME_1	31.3	147	172	152	1.54e-14	66.2
k141_28466_5	ResF|nimE_1_AJ244018_1	31.3	147	172	170	2.20e-14	66.2
k141_28466_5	megares|MEG_4184|Drugs|Metronidazole|nim_nitroimidazole_reductase|NIME_1	30.6	147	172	145	2.61e-14	65.5
k141_28466_5	NCBI|WP_005812773.1|1|1|nimE|nimE|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimE|AMR|nitroimidazole	30.6	147	172	170	4.30e-14	65.5
k141_28466_5	NCBI|WP_063854491.1|1|1|nimC|nimC|nitroimidazole_reductase|2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimC|AMR|nitroimidazole	25.2	147	172	163	5.67e-11	57.0
k141_28679_3	SARG|gb|AAC75314.1|ARO:3003578|pmrF	24.3	169	301	322	5.06e-08	52.4
k141_14907_5	SARG|YP_001605796	54.4	388	405	404	2.25e-144	415
k141_14907_5	SARG|YP_001401993	54.4	388	405	404	3.18e-144	415
k141_14907_5	SARG|YP_001871501	54.1	388	405	404	1.82e-143	413
k141_14907_5	SARG|ZP_04621517	53.8	392	405	404	5.19e-143	412
k141_14907_5	SARG|ZP_04631862	53.1	392	405	404	2.09e-142	410
k141_14907_5	SARG|YP_001477378	52.1	403	405	406	1.28e-141	408
k141_14907_5	SARG|ZP_04612558	52.7	391	405	404	4.84e-141	407
k141_14907_5	SARG|ZP_04638972	52.7	389	405	404	1.95e-140	405
k141_14907_5	SARG|ZP_04623896	54.0	376	405	380	2.46e-140	404
k141_14907_5	SARG|AAC60781	49.9	393	405	410	3.39e-122	359
k141_55500_16	SARG|gb|APB03219.1|ARO:3003986|TaeA	50.0	56	81	648	4.38e-14	64.3
k141_55500_16	NCBI|WP_063856937.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	34.2	76	81	522	3.73e-10	53.1
k141_55500_16	SARG|AAG08983	34.2	76	81	524	6.97e-10	52.4
k141_55500_16	NCBI|WP_032492560.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	34.8	69	81	522	1.78e-09	51.2
k141_55500_16	SARG|DQ823382.1.gene1.p01	34.8	69	81	522	1.78e-09	51.2
k141_55500_16	megares|MEG_7687|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	34.8	69	81	522	1.78e-09	51.2
k141_55500_16	megares|MEG_7686|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	34.8	69	81	522	1.78e-09	51.2
k141_55500_16	SARG|AAF24091	34.8	69	81	522	1.78e-09	51.2
k141_55500_16	SARG|YP_002332257	34.8	69	81	522	1.78e-09	51.2
k141_55500_16	SARG|GQ205627.2.gene1.p01	37.0	73	81	525	2.44e-09	50.8
k141_150788_23	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	33.3	129	397	639	1.07e-13	71.6
k141_150788_30	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	42.5	1313	1271	1162	0.0	958
k141_150788_30	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	41.1	1326	1271	1186	0.0	940
k141_150788_30	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	41.1	1326	1271	1186	0.0	940
k141_83187_1	SARG|gb|APB03219.1|ARO:3003986|TaeA	38.0	637	594	648	1.07e-133	404
k141_83187_1	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	531	594	655	3.24e-64	221
k141_83187_1	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.9	531	594	655	3.24e-64	221
k141_83187_1	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	531	594	655	1.19e-63	220
k141_83187_1	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	531	594	655	1.66e-63	219
k141_83187_1	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	531	594	655	1.66e-63	219
k141_83187_1	SARG|gb|AKA86814|ARO:3003746|optrA	29.8	531	594	655	1.66e-63	219
k141_83187_1	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	531	594	655	4.40e-63	218
k141_83187_1	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	531	594	655	4.40e-63	218
k141_83187_1	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	531	594	655	4.40e-63	218
k141_43609_10	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	22.0	865	904	1024	9.37e-40	158
k141_43609_10	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.0	865	904	1024	9.37e-40	158
k141_43609_10	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.0	865	904	1024	2.86e-39	156
k141_43609_10	SARG|gb|CAA53189|ARO:3000521|mupA	22.0	865	904	1024	2.86e-39	156
k141_164824_8	SARG|gb|ABA71733.1|ARO:3002972|vanTG	34.5	368	825	712	2.56e-50	187
k141_164824_8	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	33.0	373	825	711	1.52e-40	158
k141_164824_8	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	26.3	468	825	481	1.20e-39	152
k141_164824_8	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	30.9	369	825	712	1.55e-39	155
k141_164824_8	SARG|gi|498467693|ref|WP_010773049.1|	28.0	364	825	700	3.41e-39	154
k141_164824_8	SARG|JF802084.2.gene3.p01	31.3	355	825	700	4.59e-38	150
k141_164824_8	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	27.6	362	825	366	6.87e-37	141
k141_164824_8	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	26.1	463	825	451	2.46e-36	142
k141_164824_8	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	30.2	368	825	700	4.42e-34	138
k141_164824_8	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	25.4	448	825	451	7.18e-34	134
k141_44191_4	SARG|gb|CAA78046.1|ARO:3002701|Rfas_cmr	28.7	342	389	391	4.44e-25	104
k141_44191_4	megares|MEG_1781|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMRA_1	28.7	342	389	391	4.44e-25	104
k141_44191_4	SARG|YP_251195	28.7	349	389	391	2.52e-23	99.4
k141_44191_4	SARG|AF024666.2.gene33.p01	28.7	349	389	391	2.52e-23	99.4
k141_44191_4	SARG|gi|2708772|gb|AAB96371.1|	28.4	349	389	391	6.36e-23	98.2
k141_44191_4	SARG|NP_044444	28.4	349	389	391	8.65e-23	97.8
k141_165433_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.0	228	233	231	5.11e-42	141
k141_165433_2	CARD|gb|ATC67679.1|ARO:3000838|arlR	34.7	222	233	219	7.95e-38	130
k141_165433_2	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.5	223	233	219	6.24e-37	128
k141_165433_2	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.5	223	233	219	8.80e-37	127
k141_165433_2	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.5	223	233	220	9.03e-37	127
k141_165433_2	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.5	223	233	220	1.27e-36	127
k141_165433_2	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.2	226	233	232	2.45e-36	127
k141_165433_2	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	29.0	224	233	231	1.55e-29	109
k141_165433_2	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	29.3	225	233	233	1.63e-29	109
k141_165433_2	CARD|gb|ADM92605.1|ARO:3000553|adeR	28.7	230	233	247	4.40e-29	108
k141_165433_4	CARD|gb|AAD51347.1|ARO:3003067|smeS	26.9	219	224	467	5.05e-14	69.3
k141_85141_21	SARG|gi|1004359922|gb|AMP42228.1|	24.9	434	594	639	2.81e-22	100
k141_85141_21	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.4	433	594	629	3.64e-22	99.8
k141_85141_21	ResF|tet(O/W)_2_AM889119_1	25.4	433	594	639	3.73e-22	99.8
k141_85141_21	SARG|CAE46078	24.0	433	594	639	6.56e-22	99.0
k141_85141_21	SARG|P21598	24.0	433	594	639	8.71e-22	98.6
k141_85141_21	SARG|gi|291587251|gb|ADE19326.1|	24.0	433	594	644	8.81e-22	98.6
k141_85141_21	SARG|AAB05246	23.8	433	594	639	1.16e-21	98.2
k141_85141_21	SARG|ABN11268	23.8	433	594	639	1.16e-21	98.2
k141_85141_21	SARG|CAO82964	23.6	433	594	639	1.16e-21	98.2
k141_85141_21	SARG|gi|658130997|emb|CDO19407.1|	23.6	433	594	644	1.17e-21	98.2
k141_138684_27	SARG|P07287	32.1	187	269	381	9.98e-18	80.9
k141_138684_27	megares|MEG_2827|Drugs|MLS|23S_rRNA_methyltransferases|ERME_1	32.1	187	269	381	9.98e-18	80.9
k141_138684_27	SARG|P45438	32.0	181	269	287	3.26e-15	72.8
k141_138684_27	SARG|M29832.gene.p01	29.8	218	269	287	6.09e-15	72.0
k141_138684_27	SARG|Q04720	29.8	218	269	287	1.14e-14	71.2
k141_138684_27	SARG|1112175A	31.4	188	269	370	4.50e-12	64.3
k141_138684_29	SARG|gi|505052607|ref|WP_015239709.1|	41.1	107	109	112	3.16e-17	70.1
k141_138684_29	SARG|gi|494649292|ref|WP_007407236.1|	41.1	107	109	112	3.16e-17	70.1
k141_138684_29	SARG|ABS73653	41.1	107	109	112	4.47e-17	69.7
k141_138684_29	SARG|gi|489246603|ref|WP_003154767.1|	40.2	107	109	112	6.32e-17	69.3
k141_138684_29	SARG|gi|452079515|emb|CCP21271.1|	41.1	107	109	169	1.14e-16	70.1
k141_138684_29	SARG|gi|489421661|ref|WP_003327389.1|	39.0	105	109	105	3.01e-16	67.4
k141_138684_29	SARG|gi|320021335|gb|ADV96321.1|	37.4	107	109	105	3.01e-16	67.4
k141_138684_29	SARG|gi|291483835|dbj|BAI84910.1|	36.4	107	109	105	4.26e-16	67.0
k141_138684_29	SARG|gi|307606148|emb|CBI42519.1|	40.2	107	109	163	5.60e-16	68.2
k141_138684_29	SARG|gi|489311091|ref|WP_003218500.1|	36.4	107	109	105	6.02e-16	66.6
k141_138684_30	SARG|gb|AEV23046.1|ARO:3007019|fexB	22.6	199	394	469	1.87e-11	64.3
k141_58653_6	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	26.5	223	306	337	2.30e-13	68.6
k141_58653_6	SARG|AAY52004	25.2	214	306	322	3.13e-12	65.1
k141_153707_2	SARG|AAY21388	33.0	109	401	384	1.16e-10	61.6
k141_153707_2	SARG|ZP_04648601	33.0	109	401	384	1.16e-10	61.6
k141_153707_2	SARG|ZP_03982909	33.0	109	401	394	1.20e-10	61.6
k141_153707_2	SARG|ZP_03948381	33.0	109	401	394	1.20e-10	61.6
k141_153707_2	SARG|gb|BAC11911.1|ARO:3003551|emeA	31.1	103	401	393	2.09e-09	57.8
k141_46307_4	SARG|gi|857775740|emb|CRL64671.1|	29.2	445	437	457	4.63e-48	169
k141_46307_4	SARG|gi|739065857|ref|WP_036937266.1|	29.5	447	437	457	6.45e-48	169
k141_46307_4	SARG|CP004022.1.gene1427.p01	29.7	448	437	457	1.74e-47	168
k141_46307_4	SARG|gi|857587401|emb|CRL58909.1|	29.1	447	437	457	2.41e-47	167
k141_46307_46	SARG|NP_348076	28.0	683	705	652	1.28e-72	247
k141_46307_46	SARG|L42544.gene.p01	27.5	662	705	651	6.34e-71	242
k141_46307_46	SARG|AAV80410	27.3	662	705	651	2.34e-70	241
k141_46307_46	SARG|YP_002850805	26.7	686	705	652	3.07e-67	232
k141_46307_46	SARG|ZP_02952732	26.1	686	705	652	2.07e-65	227
k141_46307_46	SARG|ZP_02632674	26.1	686	705	660	2.40e-65	227
k141_46307_46	SARG|L20800.gene.p01	26.1	686	705	652	3.96e-65	226
k141_46307_46	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	27.1	661	705	641	1.13e-63	222
k141_46307_46	SARG|AAZ79478	27.1	661	705	657	1.51e-63	222
k141_46307_46	SARG|Q52360	26.9	661	705	641	1.56e-63	222
k141_6037_13	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	29.5	271	307	346	2.58e-19	85.9
k141_155127_10	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	31.3	134	153	231	2.53e-14	66.6
k141_155127_10	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	31.6	133	153	232	9.53e-14	65.1
k141_155127_10	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	31.6	133	153	232	9.53e-14	65.1
k141_155127_10	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	34.1	135	153	233	3.57e-13	63.5
k141_155127_10	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	34.5	119	153	229	6.56e-13	62.8
k141_155127_10	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	30.7	114	153	232	3.46e-12	60.8
k141_155127_10	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	29.9	134	153	230	1.24e-11	59.3
k141_155127_10	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	30.4	135	153	235	3.43e-11	58.2
k141_155127_10	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	27.4	135	153	231	3.15e-10	55.5
k141_155127_10	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	33.3	147	153	231	3.15e-10	55.5
k141_155127_17	SARG|gb|ADZ12699.1|ARO:3005091|RanA	60.5	248	258	258	2.34e-105	305
k141_155127_17	SARG|gi|754732608|ref|WP_042101370.1|	35.6	202	258	648	5.84e-27	108
k141_155127_17	SARG|gi|446110297|ref|WP_000188152.1|	35.6	202	258	648	5.84e-27	108
k141_155127_17	SARG|gi|910140813|ref|WP_050008485.1|	35.6	202	258	648	5.84e-27	108
k141_155127_17	SARG|gi|516130021|ref|WP_017560601.1|	21.3	188	258	492	6.17e-07	48.9
k141_155127_17	SARG|gi|822524709|ref|WP_046954623.1|	20.7	188	258	492	8.25e-07	48.5
k141_155127_17	SARG|gi|445983919|ref|WP_000061774.1|	20.7	188	258	492	1.10e-06	48.1
k141_155127_17	SARG|gi|445983951|ref|WP_000061806.1|	21.9	187	258	492	1.10e-06	48.1
k141_155127_17	SARG|gi|651595894|ref|WP_026590859.1|	20.3	187	258	492	1.47e-06	47.8
k141_155127_17	SARG|gi|983301550|ref|WP_060487860.1|	20.7	188	258	492	1.97e-06	47.4
k141_155127_18	SARG|gb|ADZ12700.1|ARO:3005090|RanB	45.9	244	275	253	1.92e-67	209
k141_155127_19	SARG|gi|445996710|ref|WP_000074565.1|	31.6	250	285	309	5.18e-32	119
k141_155127_19	SARG|gi|445996714|ref|WP_000074569.1|	31.0	252	285	309	1.97e-31	117
k141_155127_19	SARG|gi|895736250|emb|COF64653.1|	30.8	250	285	309	2.74e-31	117
k141_155127_19	SARG|gi|446110087|ref|WP_000187942.1|	30.8	250	285	309	5.34e-31	116
k141_155127_19	SARG|gi|445996729|ref|WP_000074584.1|	31.2	250	285	309	1.04e-30	115
k141_155127_19	SARG|gi|488053456|ref|WP_002124853.1|	31.0	255	285	309	1.04e-30	115
k141_155127_19	SARG|gi|445996719|ref|WP_000074574.1|	30.8	250	285	309	1.45e-30	115
k141_155127_19	SARG|gi|488067981|ref|WP_002139378.1|	31.0	255	285	309	2.02e-30	115
k141_155127_19	SARG|gi|487936534|ref|WP_002010000.1|	31.0	255	285	309	2.02e-30	115
k141_155127_19	SARG|gi|895808656|emb|COR83787.1|	30.4	250	285	309	2.81e-30	114
k141_140773_5	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.1	531	540	655	1.32e-67	229
k141_140773_5	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.9	531	540	655	3.55e-67	228
k141_140773_5	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.9	531	540	655	4.94e-67	228
k141_140773_5	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.7	531	540	655	4.94e-67	228
k141_140773_5	SARG|gb|AKA86814|ARO:3003746|optrA	27.7	531	540	655	4.94e-67	228
k141_140773_5	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.7	531	540	655	1.33e-66	226
k141_140773_5	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.7	531	540	655	1.33e-66	226
k141_140773_5	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.7	531	540	655	1.33e-66	226
k141_140773_5	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.7	531	540	655	1.33e-66	226
k141_140773_5	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.7	531	540	655	1.84e-66	226
k141_114580_4	SARG|gi|753914761|ref|WP_041642270.1|	29.6	385	394	418	2.07e-34	130
k141_114580_4	SARG|NC_008702.1.4609191.p01	29.8	362	394	383	8.17e-34	128
k141_114580_4	SARG|gi|506488663|ref|WP_015965124.1|	26.8	373	394	371	4.49e-32	123
k141_114580_4	SARG|CP000768.1.gene1024.p01	27.2	390	394	390	6.12e-32	123
k141_114580_4	SARG|gi|533111866|ref|WP_020975044.1|	27.7	394	394	390	6.97e-29	115
k141_114580_4	SARG|gi|488995429|ref|WP_002906142.1|	25.2	397	394	390	7.22e-26	106
k141_114580_4	SARG|gi|488943946|ref|WP_002855021.1|	25.2	397	394	390	2.52e-25	105
k141_114580_4	SARG|gi|488945956|ref|WP_002857031.1|	25.2	397	394	390	3.45e-25	104
k141_114580_4	SARG|gi|488957828|ref|WP_002868903.1|	25.2	397	394	390	3.45e-25	104
k141_114580_4	SARG|gi|488981478|ref|WP_002892307.1|	24.9	397	394	390	4.71e-25	104
k141_114580_5	SARG|gi|763407609|ref|WP_044264203.1|	44.8	230	238	648	3.91e-60	199
k141_114580_5	SARG|gi|968563772|ref|WP_058587854.1|	46.4	220	238	648	5.45e-60	198
k141_114580_5	SARG|gi|754927849|ref|WP_042284850.1|	46.8	220	238	648	5.45e-60	198
k141_114580_5	SARG|gi|757782629|ref|WP_043001213.1|	46.4	220	238	648	7.61e-60	198
k141_114580_5	SARG|gi|992390012|ref|WP_061077002.1|	46.4	220	238	648	7.61e-60	198
k141_114580_5	SARG|gi|754964360|ref|WP_042320280.1|	45.2	228	238	648	1.06e-59	197
k141_114580_5	SARG|gi|764278838|ref|WP_044327089.1|	44.8	230	238	648	1.48e-59	197
k141_114580_5	SARG|gi|742378414|ref|WP_038857601.1|	47.7	222	238	647	2.03e-59	197
k141_114580_5	SARG|gi|502669352|ref|WP_012905216.1|	45.9	220	238	648	2.06e-59	197
k141_114580_5	SARG|gi|817104523|ref|WP_046477871.1|	46.4	220	238	648	2.88e-59	196
k141_114580_6	SARG|gb|AAV85982.1|ARO:3000535|macB	39.5	405	414	644	3.15e-84	269
k141_114580_6	SARG|gi|487359045|ref|WP_001634240.1|	36.7	412	414	648	2.57e-78	253
k141_114580_6	SARG|gi|485890120|ref|WP_001482667.1|	36.7	412	414	648	2.57e-78	253
k141_114580_6	SARG|gi|446110290|ref|WP_000188145.1|	36.7	412	414	648	7.06e-78	252
k141_114580_6	SARG|gi|654658955|ref|WP_028119847.1|	36.7	412	414	648	7.06e-78	252
k141_114580_6	SARG|gi|919910427|ref|WP_052906132.1|	36.7	412	414	648	7.06e-78	252
k141_114580_6	SARG|gi|921979807|ref|WP_053271336.1|	36.7	412	414	648	7.06e-78	252
k141_114580_6	SARG|YP_002328441	36.7	412	414	648	7.06e-78	252
k141_114580_6	SARG|gi|693138751|ref|WP_032280630.1|	36.7	412	414	648	1.39e-77	251
k141_114580_6	SARG|gi|446110334|ref|WP_000188189.1|	36.7	412	414	648	1.39e-77	251
k141_114699_4	SARG|gi|313614636|gb|EFR88215.1|	24.3	424	445	453	6.65e-41	150
k141_114699_4	SARG|gi|313638554|gb|EFS03703.1|	25.1	427	445	453	9.20e-41	150
k141_114699_4	SARG|gi|441473784|emb|CCQ23538.1|	25.5	318	445	336	5.23e-27	109
k141_114699_4	SARG|HE999704.1.gene1126.p01	24.4	315	445	337	5.32e-27	109
k141_114699_4	SARG|gi|313619623|gb|EFR91268.1|	29.5	193	445	237	1.14e-24	100
k141_155695_50	SARG|ZP_02889084	33.1	338	401	405	5.73e-42	151
k141_155695_50	SARG|YP_001811891	32.8	338	401	405	7.97e-42	150
k141_155695_50	SARG|YP_776583	32.8	338	401	405	7.97e-42	150
k141_155695_50	SARG|YP_002235155	33.1	338	401	405	1.11e-41	150
k141_155695_50	SARG|YP_371055	32.8	338	401	405	2.15e-41	149
k141_155695_50	SARG|gi|746321235|ref|WP_039367880.1|	32.5	338	401	405	2.98e-41	149
k141_155695_50	SARG|gi|736027032|ref|WP_034187788.1|	32.5	338	401	405	2.98e-41	149
k141_155695_50	SARG|gi|667783307|ref|WP_031401782.1|	32.8	338	401	405	4.15e-41	149
k141_155695_50	SARG|gi|759459593|ref|WP_043180924.1|	32.8	338	401	405	5.77e-41	148
k141_155695_50	SARG|ZP_02904981	32.9	337	401	405	1.11e-40	147
k141_155695_51	NCBI|AAN29241.1|1|1|bepE|bepE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepE|AMR|efflux	40.8	1057	1084	1051	3.49e-247	727
k141_155695_51	NCBI|AAN33534.1|1|1|bepG|bepG|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepG|AMR|efflux	38.8	1043	1084	1074	7.54e-240	709
k141_155695_51	SARG|gi|940169821|gb|KPX83830.1|	38.9	1044	1084	1059	2.12e-228	679
k141_155695_51	SARG|gi|780147796|ref|WP_045491627.1|	38.5	1049	1084	1063	5.26e-227	675
k141_155695_51	SARG|gi|950554518|ref|WP_057427257.1|	38.3	1054	1084	1060	3.78e-226	673
k141_155695_51	SARG|gi|514421161|ref|WP_016568324.1|	38.5	1051	1084	1063	5.82e-226	672
k141_155695_51	SARG|gi|490552377|ref|WP_004417486.1|	38.4	1051	1084	1063	1.16e-225	672
k141_155695_51	SARG|gi|489512421|ref|WP_003417270.1|	38.4	1051	1084	1063	1.16e-225	672
k141_155695_51	SARG|gi|639494054|ref|WP_024665043.1|	38.4	1051	1084	1063	2.30e-225	671
k141_155695_51	SARG|gi|950580033|ref|WP_057445338.1|	38.4	1051	1084	1063	2.30e-225	671
k141_155695_52	NCBI|CAQ45062.1|1|1|emrC|emrC||1|EFFLUX|EFFLUX|multidrug_efflux_transporter_outer_membrane_subunit_EmrC|AMR|efflux	24.0	487	460	497	1.78e-14	74.3
k141_155695_52	SARG|CP000675.2.gene498.p01	24.0	258	460	447	7.87e-11	62.8
k141_155695_57	SARG|ZP_04294082	35.1	265	266	263	2.69e-43	147
k141_155695_57	SARG|ZP_04196507	34.7	265	266	263	1.06e-42	145
k141_155695_57	SARG|ZP_04202328	34.3	265	266	263	1.49e-42	145
k141_155695_57	SARG|ZP_04173668	34.3	265	266	263	1.49e-42	145
k141_155695_57	SARG|ZP_04167983	34.7	265	266	263	2.10e-42	144
k141_155695_57	SARG|ZP_04288431	34.3	265	266	263	2.96e-42	144
k141_155695_57	SARG|NP_977823	34.3	265	266	263	2.96e-42	144
k141_155695_57	SARG|YP_001644180	34.7	265	266	263	2.96e-42	144
k141_155695_57	SARG|ZP_04299687	34.7	265	266	263	4.17e-42	144
k141_155695_57	SARG|ZP_04144736	34.3	265	266	263	8.27e-42	143
k141_87428_15	SARG|YP_606823	26.6	319	322	1011	3.53e-28	114
k141_87428_15	SARG|YP_001266290	24.8	315	322	1014	7.20e-27	110
k141_87428_15	SARG|YP_001670703	25.3	316	322	1014	1.08e-25	106
k141_87428_15	SARG|YP_001186705	24.8	314	322	1017	1.08e-25	106
k141_87428_15	SARG|YP_001350280	24.4	311	322	1018	2.67e-25	105
k141_87428_15	SARG|YP_350221	23.8	319	322	1009	4.86e-25	104
k141_87428_15	SARG|YP_792720	24.1	311	322	1018	1.62e-24	103
k141_87428_15	SARG|AAG07763	24.1	311	322	1018	1.62e-24	103
k141_87428_15	SARG|CAY51926	23.5	311	322	1008	2.18e-24	102
k141_87428_15	SARG|gb|AAG07064.1|ARO:3003693|mexK	27.1	292	322	1025	2.41e-23	99.8
k141_87428_16	SARG|gb|CAH14033.1|ARO:3004100|LpeB	27.3	598	712	1014	3.65e-55	203
k141_87428_16	SARG|YP_792720	25.1	650	712	1018	6.73e-55	202
k141_87428_16	SARG|AAG07763	25.1	650	712	1018	9.07e-55	202
k141_87428_16	SARG|YP_001350280	25.2	650	712	1018	2.22e-54	201
k141_87428_16	SARG|YP_350221	25.2	650	712	1009	3.91e-54	200
k141_87428_16	SARG|CAY51926	24.9	650	712	1008	5.24e-54	199
k141_87428_16	SARG|YP_001186705	24.6	650	712	1017	4.34e-53	197
k141_87428_16	SARG|YP_001266290	24.8	650	712	1014	2.02e-51	192
k141_87428_16	SARG|YP_001670703	26.5	499	712	1014	4.91e-51	191
k141_87428_16	SARG|YP_606823	26.3	543	712	1011	1.25e-49	186
k141_7670_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	28.8	160	1352	231	1.82e-13	70.5
k141_7670_2	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	27.9	136	1352	220	1.24e-12	67.8
k141_7670_2	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.6	126	1352	219	4.07e-12	66.2
k141_7670_2	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.6	126	1352	219	4.07e-12	66.2
k141_7670_2	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.6	126	1352	220	4.14e-12	66.2
k141_7670_2	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.6	126	1352	220	7.56e-12	65.5
k141_7670_2	SARG|ZP_02848503	27.0	126	1352	221	2.31e-09	58.2
k141_7670_2	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	33.8	136	1352	231	2.66e-09	58.2
k141_7670_2	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	28.0	118	1352	225	1.24e-06	50.1
k141_7670_2	CARD|gb|AAC73788.1|ARO:3003841|kdpE	28.0	118	1352	225	1.24e-06	50.1
k141_87497_7	SARG|gi|728044173|ref|WP_033910180.1|	25.0	352	371	392	3.73e-30	118
k141_87497_7	SARG|gi|844693715|ref|WP_047919963.1|	24.7	352	371	392	5.14e-30	117
k141_87497_7	SARG|gi|489796383|ref|WP_003700274.1|	24.7	352	371	392	5.14e-30	117
k141_87497_7	SARG|gi|844722982|ref|WP_047924275.1|	24.7	352	371	392	7.09e-30	117
k141_87497_7	SARG|gi|844730941|ref|WP_047926220.1|	25.0	352	371	392	7.09e-30	117
k141_87497_7	SARG|gi|728045764|ref|WP_033911415.1|	24.7	352	371	426	8.10e-30	117
k141_87497_7	SARG|gi|856831580|ref|WP_048339545.1|	24.7	352	371	392	9.77e-30	117
k141_87497_7	SARG|gi|489793501|ref|WP_003697392.1|	24.7	352	371	392	9.77e-30	117
k141_87497_7	SARG|gi|911859034|ref|WP_050157472.1|	24.7	352	371	392	9.77e-30	117
k141_87497_7	SARG|gi|489789789|ref|WP_003693680.1|	24.7	352	371	392	9.77e-30	117
k141_87497_8	SARG|gi|495736522|ref|WP_008461101.1|	25.9	401	416	648	1.45e-28	117
k141_87497_8	SARG|gi|746243059|ref|WP_039291473.1|	25.9	401	416	648	1.45e-28	117
k141_87497_8	SARG|gi|746253210|ref|WP_039301529.1|	25.9	401	416	648	1.45e-28	117
k141_87497_8	SARG|gi|1001720867|ref|WP_061274204.1|	25.9	401	416	648	1.45e-28	117
k141_87497_8	SARG|gb|AAV85982.1|ARO:3000535|macB	27.0	400	416	644	3.51e-28	115
k141_87497_8	SARG|gi|495067432|ref|WP_007792257.1|	25.1	402	416	647	1.17e-27	114
k141_87497_8	SARG|YP_001438541	25.1	402	416	647	2.85e-27	113
k141_87497_8	SARG|gi|938460528|ref|WP_054624864.1|	25.1	402	416	647	2.85e-27	113
k141_87497_8	SARG|gi|490522515|ref|WP_004387938.1|	25.1	402	416	647	2.85e-27	113
k141_87497_8	SARG|gi|696420214|ref|WP_032990021.1|	25.1	402	416	647	2.85e-27	113
k141_87497_9	SARG|gi|556235879|ref|WP_023284905.1|	22.1	426	421	646	2.41e-19	89.4
k141_87497_9	SARG|gi|742128296|gb|AJA96431.1|	22.1	426	421	646	2.41e-19	89.4
k141_87497_9	SARG|gi|1031822889|ref|WP_064150402.1|	22.1	426	421	646	3.21e-19	89.0
k141_87497_9	SARG|gi|490306253|ref|WP_004201358.1|	22.1	426	421	646	3.21e-19	89.0
k141_87497_9	SARG|gi|895903124|ref|WP_049003730.1|	22.1	426	421	646	3.21e-19	89.0
k141_87497_9	SARG|gi|516510995|ref|WP_017899433.1|	22.1	426	421	646	3.21e-19	89.0
k141_87497_9	SARG|gi|1043941253|emb|SBY03087.1|	22.1	426	421	646	3.21e-19	89.0
k141_87497_9	SARG|gi|896073592|ref|WP_049116987.1|	22.1	426	421	646	3.21e-19	89.0
k141_87497_9	SARG|gi|694113840|ref|WP_032455777.1|	22.1	426	421	646	3.21e-19	89.0
k141_87497_9	SARG|gi|1031873672|ref|WP_064188664.1|	22.1	426	421	646	3.21e-19	89.0
k141_87497_10	SARG|gi|643601187|ref|WP_025237288.1|	47.5	240	256	648	4.76e-63	207
k141_87497_10	SARG|gi|974628291|ref|WP_059215695.1|	47.5	240	256	648	4.76e-63	207
k141_87497_10	SARG|gi|446110298|ref|WP_000188153.1|	47.5	240	256	648	4.76e-63	207
k141_87497_10	SARG|gi|974633183|ref|WP_059219858.1|	47.5	240	256	648	4.76e-63	207
k141_87497_10	SARG|gi|974684692|ref|WP_059267998.1|	47.5	240	256	648	4.76e-63	207
k141_87497_10	SARG|gi|974672242|ref|WP_059256507.1|	47.5	240	256	648	6.64e-63	207
k141_87497_10	SARG|gi|974641719|ref|WP_059227752.1|	47.5	240	256	648	6.64e-63	207
k141_87497_10	SARG|gi|446110299|ref|WP_000188154.1|	47.5	240	256	648	6.64e-63	207
k141_87497_10	SARG|ZP_02903696	47.5	240	256	648	6.64e-63	207
k141_87497_10	SARG|gi|974688082|ref|WP_059271287.1|	47.5	240	256	648	6.64e-63	207
k141_141393_1	SARG|M80346.gene.p01	33.9	496	489	551	1.17e-52	185
k141_141393_1	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	33.9	496	489	551	1.17e-52	185
k141_141393_1	SARG|X63451.gene.p01	31.2	504	489	550	3.86e-48	173
k141_141393_1	megares|MEG_6558|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|SRMB_1	31.2	504	489	550	3.86e-48	173
k141_141393_1	SARG|gb|NP_388442.1|ARO:3004476|vmlR	28.3	508	489	547	7.04e-48	172
k141_141393_1	SARG|gi|488321355|ref|WP_002390740.1|	30.1	489	489	492	5.68e-37	141
k141_141393_1	SARG|gb|MBW0764195.1|ARO:3007027|salC	25.8	473	489	541	3.16e-35	137
k141_141393_1	SARG|AY004350.gene.p01	29.7	489	489	492	6.34e-35	135
k141_141393_1	SARG|gi|488231473|ref|WP_002302681.1|	29.0	486	489	492	1.62e-34	134
k141_141393_1	SARG|gi|488216250|ref|WP_002287458.1|	29.0	486	489	492	1.62e-34	134
k141_21240_12	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.3	214	394	381	4.49e-08	53.5
k141_21240_12	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.3	214	394	381	4.49e-08	53.5
k141_21240_12	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	23.1	199	394	381	4.37e-07	50.4
k141_21240_12	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	23.1	199	394	381	4.37e-07	50.4
k141_21240_12	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	23.7	215	394	381	1.36e-06	48.9
k141_21240_12	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	23.7	215	394	381	1.36e-06	48.9
k141_48305_6	CARD|gb|AAC75429.1|ARO:3000833|evgS	25.6	395	973	1197	4.58e-33	137
k141_48305_6	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	29.3	184	973	228	3.46e-19	86.7
k141_48305_6	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.3	118	973	219	5.24e-19	85.9
k141_48305_6	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.9	122	973	232	1.21e-16	79.3
k141_48305_6	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	33.6	128	973	233	1.23e-16	79.3
k141_48305_6	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	34.5	119	973	235	1.28e-16	79.3
k141_48305_6	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	32.7	171	973	252	2.37e-16	79.0
k141_48305_6	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	32.3	124	973	231	7.31e-16	77.0
k141_48305_6	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	27.9	201	973	359	5.71e-15	76.6
k141_48305_6	CARD|gb|AAD51348.1|ARO:3003066|smeR	38.5	91	973	229	1.07e-14	73.6
k141_8083_1	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	33.5	498	498	1024	1.80e-87	288
k141_8083_1	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	33.5	498	498	1024	1.80e-87	288
k141_8083_1	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	33.3	496	498	1033	5.25e-86	284
k141_8083_1	SARG|gb|AEY83581|ARO:3000510|mupB	33.3	496	498	1033	5.25e-86	284
k141_8083_1	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	33.1	498	498	1024	1.73e-85	283
k141_8083_1	SARG|gb|CAA53189|ARO:3000521|mupA	33.1	498	498	1024	1.73e-85	283
k141_169747_2	SARG|AAN28721	74.3	74	393	108	4.30e-38	132
k141_156728_1	SARG|gb|AAC75089.1|ARO:3003577|ugd	60.9	235	236	388	1.05e-95	284
k141_210727_1	SARG|gi|1001786599|ref|WP_061324791.1|	29.0	389	755	563	8.07e-37	145
k141_210727_1	SARG|YP_001477377	29.0	389	755	563	1.08e-36	144
k141_210727_1	SARG|ZP_04631861	30.5	383	755	543	3.81e-36	142
k141_210727_1	SARG|ZP_04612557	30.0	383	755	543	6.89e-36	142
k141_210727_1	SARG|gi|544012122|gb|ERK10884.1|	28.7	383	755	541	1.22e-35	141
k141_210727_1	SARG|gi|896190680|ref|WP_049199932.1|	28.8	389	755	563	2.08e-35	140
k141_210727_1	SARG|ZP_04638974	29.2	390	755	563	2.08e-35	140
k141_210727_1	SARG|ZP_04635128	30.1	375	755	543	4.07e-35	139
k141_210727_1	SARG|YP_001007250	28.9	401	755	563	5.04e-35	139
k141_210727_1	SARG|YP_001401994	29.8	382	755	563	5.04e-35	139
k141_116758_2	megares|MEG_730|Drugs|beta-lactam|Penicillin_binding_protein|AMPH_1	26.6	169	448	386	5.27e-06	47.4
k141_103761_9	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	38.0	158	157	159	1.37e-30	107
k141_103761_25	SARG|gi|671541568|ref|WP_031525212.1|	32.5	83	410	648	9.06e-08	53.1
k141_62803_30	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	25.0	556	550	579	1.19e-45	168
k141_62803_30	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	24.8	565	550	579	2.25e-45	167
k141_62803_30	SARG|gb|WP_104671188.1|ARO:3003948|efrA	31.2	292	550	575	6.01e-34	134
k141_62803_30	SARG|gi|748767925|ref|WP_040019608.1|	24.9	566	550	623	2.08e-33	133
k141_62803_30	SARG|gi|664085850|ref|WP_030624018.1|	25.7	564	550	605	4.56e-33	132
k141_62803_30	SARG|gb|CDO61516.1|ARO:3003949|efrB	30.5	266	550	362	1.30e-32	127
k141_62803_30	SARG|gi|1033217078|gb|OAR27197.1|	24.1	556	550	601	3.60e-32	129
k141_62803_30	SARG|gi|664458452|ref|WP_030980047.1|	24.2	554	550	601	6.53e-32	129
k141_62803_30	SARG|gi|501350226|ref|WP_012381861.1|	25.4	566	550	603	8.90e-32	128
k141_62803_30	SARG|gi|664170108|ref|WP_030704355.1|	25.3	566	550	603	2.17e-31	127
k141_103822_14	SARG|gi|851899656|ref|WP_048211088.1|	26.8	295	325	660	5.77e-25	104
k141_103822_14	SARG|gi|489117806|ref|WP_003027650.1|	27.5	295	325	660	7.79e-25	103
k141_103822_14	SARG|gi|696375142|ref|WP_032949690.1|	28.9	266	325	660	7.79e-25	103
k141_103822_14	SARG|gi|765458296|ref|WP_044714032.1|	28.9	266	325	660	1.05e-24	103
k141_103822_14	SARG|gi|851928593|ref|WP_048220996.1|	27.1	295	325	660	1.42e-24	103
k141_103822_14	SARG|gi|1002399350|ref|WP_061382108.1|	30.3	241	325	660	1.42e-24	103
k141_103822_14	SARG|gi|757799830|ref|WP_043017032.1|	29.5	241	325	660	1.92e-24	102
k141_103822_14	SARG|gi|507079934|ref|WP_016150692.1|	28.6	266	325	660	3.51e-24	102
k141_103822_14	SARG|gi|851981245|ref|WP_048240645.1|	28.9	266	325	660	3.51e-24	102
k141_103822_14	SARG|gi|507086291|ref|WP_016157032.1|	31.0	226	325	660	6.39e-24	101
k141_103822_21	NCBI|ACF30254.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	33.3	69	198	210	1.63e-06	45.8
k141_103822_21	NCBI|CAA81047.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	33.3	69	198	210	1.63e-06	45.8
k141_103822_27	SARG|gi|447057510|ref|WP_001134766.1|	27.2	272	259	309	3.01e-28	108
k141_103822_27	SARG|gi|488042066|ref|WP_002113463.1|	27.2	272	259	309	1.13e-27	107
k141_103822_27	SARG|gi|488130770|ref|WP_002201978.1|	26.1	272	259	309	1.58e-27	106
k141_103822_27	SARG|gi|447057509|ref|WP_001134765.1|	26.5	272	259	309	2.20e-27	106
k141_103822_27	SARG|gi|488068784|ref|WP_002140181.1|	26.5	272	259	309	2.20e-27	106
k141_103822_27	SARG|gi|507023808|ref|WP_016095885.1|	26.1	272	259	309	3.06e-27	105
k141_103822_27	SARG|gi|542061059|gb|ERI11611.1|	27.2	239	259	316	6.67e-27	105
k141_103822_27	SARG|gi|445996719|ref|WP_000074574.1|	26.1	272	259	309	8.25e-27	104
k141_103822_27	SARG|gi|1043490477|ref|WP_065382463.1|	26.1	272	259	309	8.25e-27	104
k141_103822_27	SARG|gi|445996726|ref|WP_000074581.1|	26.1	272	259	309	8.25e-27	104
k141_103822_28	SARG|gi|1035706844|ref|WP_064548272.1|	31.0	100	941	648	2.45e-07	53.5
k141_50326_1	SARG|ZP_02952732	31.6	76	489	652	6.07e-06	47.8
k141_50326_1	SARG|L20800.gene.p01	31.6	76	489	652	6.07e-06	47.8
k141_50326_1	SARG|ZP_02632674	31.6	76	489	660	6.09e-06	47.8
k141_185151_8	SARG|gb|BAD63613.1|ARO:3002816|clbC	30.1	335	353	350	1.59e-42	150
k141_185151_8	SARG|gb|ACX65640.1|ARO:3003907|cipA	27.0	337	353	346	3.20e-39	141
k141_185151_11	CARD|gb|AAK37618.1|ARO:3005008|TxR	42.9	231	408	318	5.03e-63	204
k141_50747_11	SARG|CAE53424	35.4	164	160	169	5.59e-27	98.6
k141_50747_11	SARG|CAX16467	43.9	132	160	165	7.12e-27	98.2
k141_50747_11	SARG|gb|CAF31623.1|ARO:3005354|dfr22	43.9	132	160	165	7.12e-27	98.2
k141_50747_11	NCBI|WP_071846242.1|1|1|dfrA33|dfrA33|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA33|AMR|diaminopyrimidine	43.9	132	160	165	1.01e-26	97.8
k141_50747_11	NCBI|WP_434062363.1|1|1|dfrA53|dfrA53|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA53|AMR|diaminopyrimidine	40.4	161	160	166	2.90e-26	96.7
k141_50747_11	SARG|gb|AAO04716.1|ARO:3002865|dfrC	38.8	160	160	161	5.09e-26	95.9
k141_50747_11	NCBI|WP_000175735.1|1|1|dfrS1|dfrC|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrS1|AMR|diaminopyrimidine	38.8	160	160	161	7.19e-26	95.5
k141_50747_11	SARG|gb|AGY30828.1|ARO:3003018|dfrA22	43.4	129	160	165	1.12e-25	95.1
k141_50747_11	SARG|ACR66838	43.4	129	160	165	1.59e-25	94.7
k141_50747_11	NCBI|WP_012655890.1|1|1|dfrE|dfrE|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrE|AMR|diaminopyrimidine	35.7	129	160	164	6.82e-24	90.5
k141_50875_2	SARG|gb|AAC75089.1|ARO:3003577|ugd	56.5	434	441	388	3.28e-164	466
k141_158985_19	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	28.8	621	631	633	4.70e-64	221
k141_158985_19	SARG|gb|AQX82857.1|ARO:3004185|mecD	25.7	534	631	678	1.45e-28	120
k141_158985_19	megares|MEG_3790|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	25.1	459	631	666	4.37e-28	118
k141_158985_19	SARG|CAA70425	24.0	546	631	666	5.81e-28	118
k141_158985_19	NCBI|WP_128268231.1|1|1|mecC2|mecC2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC2|AMR|beta-lactam	24.2	530	631	665	1.03e-27	117
k141_158985_19	SARG|gi|2791908|emb|CAA73538.1|	23.6	546	631	666	1.03e-27	117
k141_158985_19	megares|MEG_3792|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	23.6	546	631	666	1.37e-27	117
k141_158985_19	SARG|gb|BAI83385.1|ARO:3003440|mecB	24.7	421	631	674	4.39e-27	115
k141_158985_19	SARG|AAX35723	24.7	445	631	665	1.78e-26	113
k141_158985_19	megares|MEG_3800|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	23.1	532	631	665	2.36e-26	113
k141_185547_4	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	25.1	223	302	578	3.05e-11	62.8
k141_185547_4	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.0	183	302	655	4.45e-09	56.2
k141_185547_4	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.0	183	302	655	7.92e-09	55.5
k141_185547_4	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.0	183	302	655	7.92e-09	55.5
k141_185547_4	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.0	183	302	655	7.92e-09	55.5
k141_185547_4	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.0	183	302	655	7.92e-09	55.5
k141_185547_4	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.0	183	302	655	7.92e-09	55.5
k141_185547_4	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.0	183	302	655	7.92e-09	55.5
k141_185547_4	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.0	183	302	655	7.92e-09	55.5
k141_185547_4	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.0	183	302	655	1.06e-08	55.1
k141_104338_1	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	36.5	682	713	1033	1.80e-139	434
k141_104338_1	SARG|gb|AEY83581|ARO:3000510|mupB	36.5	682	713	1033	1.80e-139	434
k141_104338_1	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	34.2	693	713	1107	2.03e-117	377
k141_104338_1	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	34.2	693	713	1107	2.03e-117	377
k141_104338_1	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	37.2	409	713	1024	4.27e-77	266
k141_104338_1	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	37.2	409	713	1024	4.27e-77	266
k141_104338_1	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	37.2	409	713	1024	4.27e-77	266
k141_104338_1	SARG|gb|CAA53189|ARO:3000521|mupA	37.2	409	713	1024	4.27e-77	266
k141_104900_3	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	36.7	534	542	533	3.33e-93	293
k141_104900_3	SARG|AF353562.gene.p01	35.1	367	542	369	2.11e-49	173
k141_91444_10	CARD|gb|AAC75429.1|ARO:3000833|evgS	28.2	227	1024	1197	8.31e-25	110
k141_91444_29	SARG|gb|AAC75314.1|ARO:3003578|pmrF	32.9	322	324	322	3.72e-44	152
k141_145974_7	SARG|AAV80410	28.5	446	523	651	3.21e-42	159
k141_145974_7	SARG|L42544.gene.p01	28.3	446	523	651	2.06e-41	156
k141_145974_7	SARG|AJ514254.gene.p01	28.3	456	523	640	1.91e-37	145
k141_145974_7	SARG|FN594949.1.gene24.p01	27.7	459	523	640	1.82e-35	139
k141_145974_7	NCBI|WP_003454408.1|1|1|tet(44)|tet(44)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(44)|AMR|tetracycline	28.0	464	523	640	4.51e-35	138
k141_145974_7	NCBI|WP_032490535.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	27.7	462	523	639	2.73e-34	135
k141_145974_7	SARG|AAW34142	27.7	462	523	639	3.69e-34	135
k141_145974_7	SARG|CAA37477	25.8	469	523	663	2.90e-31	127
k141_132904_13	SARG|gi|730552397|ref|WP_034045676.1|	21.5	372	416	387	8.59e-07	49.7
k141_132904_13	SARG|gi|730318750|ref|WP_033983530.1|	21.5	372	416	387	8.59e-07	49.7
k141_132904_13	SARG|gi|730568754|ref|WP_034049402.1|	21.2	372	416	387	8.59e-07	49.7
k141_132904_13	SARG|gi|685917389|ref|WP_031654226.1|	21.5	372	416	387	1.14e-06	49.3
k141_132904_13	SARG|gi|730493281|ref|WP_034028540.1|	21.5	372	416	387	1.51e-06	48.9
k141_132904_13	SARG|gi|730504939|ref|WP_034031532.1|	21.5	372	416	387	1.51e-06	48.9
k141_132904_13	SARG|gi|685953935|ref|WP_031675562.1|	21.5	372	416	387	1.51e-06	48.9
k141_132904_13	SARG|gi|685892102|ref|WP_031633341.1|	21.5	372	416	387	1.51e-06	48.9
k141_132904_13	SARG|gi|730539214|ref|WP_034040500.1|	21.5	372	416	387	1.51e-06	48.9
k141_132904_13	SARG|gi|490482422|ref|WP_004352726.1|	21.5	372	416	387	1.51e-06	48.9
k141_132904_14	SARG|gi|823326845|ref|WP_047080664.1|	45.7	219	227	648	5.30e-59	195
k141_132904_14	SARG|gi|896325272|ref|WP_049294291.1|	44.7	219	227	648	5.30e-59	195
k141_132904_14	SARG|gi|823302270|ref|WP_047057473.1|	45.7	219	227	648	1.03e-58	194
k141_132904_14	SARG|gi|976146774|ref|WP_059305359.1|	45.7	219	227	648	1.03e-58	194
k141_132904_14	SARG|gi|1022664304|ref|WP_063420886.1|	45.7	219	227	648	1.03e-58	194
k141_132904_14	SARG|gi|823309640|ref|WP_047064288.1|	45.7	219	227	648	1.03e-58	194
k141_132904_14	SARG|gi|505807117|ref|WP_015704872.1|	45.7	219	227	648	1.03e-58	194
k141_132904_14	SARG|gi|518923394|ref|WP_020079269.1|	45.7	219	227	648	1.03e-58	194
k141_132904_14	SARG|gi|695797094|ref|WP_032711285.1|	45.7	219	227	648	1.03e-58	194
k141_132904_14	SARG|gi|823299155|ref|WP_047054544.1|	45.7	219	227	648	1.03e-58	194
k141_91625_3	SARG|NP_878015	33.7	276	318	322	1.96e-33	124
k141_91625_3	NCBI|WP_063856710.1|1|1|vanH-Pt2|vanH-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Pt2|AMR|glycopeptide	35.6	261	318	322	2.74e-33	124
k141_91625_3	SARG|AAY52004	33.7	276	318	322	3.82e-33	123
k141_91625_3	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	33.2	286	318	343	1.54e-32	122
k141_91625_3	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	37.1	264	318	323	7.68e-32	120
k141_91625_3	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	33.2	283	318	348	8.76e-32	120
k141_91625_3	SARG|gb|AAB05626.1|ARO:3002943|vanHB	36.9	263	318	323	1.49e-31	119
k141_91625_3	SARG|AF310956.2.gene5.p01	38.1	252	318	323	2.07e-31	119
k141_91625_3	SARG|Q47748	36.9	263	318	323	2.88e-31	118
k141_91625_3	SARG|gi|498515089|ref|WP_010815296.1|	36.9	263	318	323	4.01e-31	118
k141_91683_1	SARG|gb|AAK76136.1|ARO:3000025|patB	27.8	593	729	588	2.79e-47	176
k141_91683_1	SARG|gi|943938624|ref|WP_055567802.1|	38.9	247	729	602	3.41e-47	176
k141_91683_1	SARG|gi|517381192|ref|WP_018555350.1|	28.1	569	729	602	3.41e-47	176
k141_91683_1	SARG|gb|AAC74000.1|ARO:3003950|msbA	27.2	515	729	582	8.80e-47	174
k141_91683_1	SARG|gi|943909899|ref|WP_055545300.1|	38.5	247	729	601	1.15e-46	174
k141_91683_1	SARG|gi|517347347|ref|WP_018522839.1|	27.9	567	729	601	1.15e-46	174
k141_91683_1	SARG|gi|496018010|ref|WP_008742581.1|	38.4	242	729	623	2.10e-46	174
k141_91683_1	SARG|gi|944152509|ref|WP_055644808.1|	27.5	560	729	616	2.61e-46	173
k141_91683_1	SARG|gi|516574297|ref|WP_017949361.1|	28.1	563	729	620	5.06e-46	172
k141_91683_1	SARG|gi|739906046|ref|WP_037756452.1|	27.3	560	729	620	6.88e-46	172
k141_146801_1	NCBI|QEY54480.1|1|1|mcr-11.1|mcr-11||1|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-11.1|AMR|peptide	26.4	451	576	539	4.96e-29	120
k141_146801_1	ResF|mcr-8.5_1_MN836537_1	28.0	425	576	472	2.21e-28	117
k141_146801_1	NCBI|WP_181726036.1|1|1|mcr-8.5|mcr-8||2|||phosphoethanolamine--lipid_A_transferase_MCR-8.5|AMR|peptide	28.0	425	576	565	4.62e-28	117
k141_146801_1	ResF|mcr-8_1_MG736312_1	28.0	425	576	472	7.29e-28	115
k141_146801_1	ResF|mcr-8.2_1_MH638291_1	28.0	425	576	472	7.29e-28	115
k141_146801_1	ResF|mcr-8.3_1_MH598530_1	28.0	425	576	472	7.29e-28	115
k141_146801_1	ResF|mcr-8.4_1_MH791448_1	28.0	425	576	472	7.29e-28	115
k141_146801_1	NCBI|WP_208595319.1|1|1|mcr-10.4|mcr-10||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-10.4|AMR|peptide	27.3	454	576	539	9.44e-28	116
k141_146801_1	SARG|gb|QDO66747.1|ARO:3007137|mcr-10.1	27.3	454	576	539	1.27e-27	115
k141_146801_1	NCBI|WP_150823497.1|1|1|mcr-8.3|mcr-8||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-8.3|AMR|peptide	28.0	425	576	565	1.49e-27	115
k141_146801_5	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	25.5	715	648	703	1.34e-39	154
k141_92882_13	CARD|gb|AAG03548.1|ARO:3003681|TriC	21.9	474	532	1015	3.18e-27	115
k141_92882_13	CARD|gb|AAC75136.1|ARO:3000793|mdtB	22.9	536	532	1040	1.36e-26	113
k141_92882_13	SARG|gb|AAG05915.1|ARO:3004074|MuxB	23.0	540	532	1043	2.05e-20	94.4
k141_92882_13	SARG|YP_001186705	25.4	339	532	1017	8.56e-16	79.7
k141_92882_13	CARD|gb|AAG07594.1|ARO:3000808|MexI	22.7	330	532	1029	1.14e-15	79.3
k141_92882_13	SARG|YP_001266290	25.8	310	532	1014	1.97e-15	78.6
k141_92882_13	SARG|YP_001670703	24.4	349	532	1014	1.97e-15	78.6
k141_92882_13	SARG|gb|BAE06006.1|ARO:3003705|mexN	24.8	331	532	1036	6.06e-15	77.0
k141_92882_13	SARG|YP_350221	23.8	303	532	1009	3.18e-14	74.7
k141_92882_13	SARG|YP_606823	25.2	314	532	1011	3.18e-14	74.7
k141_40270_7	SARG|ZP_02848503	33.9	112	517	221	1.97e-11	62.8
k141_40270_7	CARD|gb|AAG06465.1|ARO:3005063|cprR	25.4	118	517	223	2.45e-09	56.6
k141_40270_11	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.7	230	230	231	1.84e-41	140
k141_40270_11	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.4	229	230	229	1.38e-40	137
k141_40270_11	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	34.3	230	230	231	4.08e-40	136
k141_40270_11	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.3	230	230	231	4.08e-40	136
k141_40270_11	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.4	223	230	219	5.87e-40	135
k141_40270_11	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.8	230	230	231	8.12e-40	135
k141_40270_11	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.9	230	230	231	6.39e-39	133
k141_40270_11	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.9	227	230	228	6.53e-38	130
k141_40270_11	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	34.7	236	230	235	7.84e-38	130
k141_40270_11	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	36.5	230	230	231	1.10e-36	127
k141_40270_12	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	32.2	227	476	367	1.35e-30	120
k141_40270_12	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	32.2	227	476	368	1.37e-30	120
k141_40270_12	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	32.6	227	476	381	4.36e-30	119
k141_40270_12	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	32.6	227	476	381	4.36e-30	119
k141_40270_12	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	29.1	247	476	370	8.45e-29	115
k141_40270_12	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.8	312	476	381	3.48e-28	114
k141_40270_12	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.8	312	476	381	3.48e-28	114
k141_40270_12	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.8	312	476	381	4.75e-28	114
k141_40270_12	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.8	312	476	381	4.75e-28	114
k141_40270_12	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	28.4	250	476	365	9.52e-28	112
